<DOC>
	<DOCNO>NCT01566617</DOCNO>
	<brief_summary>The investigator hypothesize pharmaceutical care may constitute important tool clinical management patient improve compliance treatment consequent improvement quality life minimize symptom , decrease number hospital admission adverse drug reaction . Therefore , aim trial evaluate contribution pharmaceutical care clinical treatment patient Chagas heart disease complicate heart failure . Study Type : Interventional Study Design : A total 88 patient randomly assign two parallel group : ( 1 ) group receive standard care pharmaceutical care ; ( 2 ) group receive standard care . Both group subject follow-up period 12 month . The primary outcome trial evaluation quality life , measure 36-item short-form Minnesota Living Heart Failure Questionnaire . Secondary outcome include drug-related problem exercise tolerance measure standard six-minute walk test .</brief_summary>
	<brief_title>Impact Pharmaceutical Care Quality Life Patients With Chagas Heart Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>The propose clinical trial conduct volunteer Chagas disease complicate heart failure . Subjects include adult , men woman , racial ethnic minority . Diagnosed two distinct Chagas serology test ( indirect immunofluorescence enzyme link immunosorbent assay Patients comorbidities significantly affect cardiac performance , coronary artery disease , moderate severe heart valvular disease , leave ventricular ( LV ) hypertrophy , congenital heart disease , limit survival , malignant tumor HIV , exclude study . Patients also exclude case failure give inform consent , inability perform 6 minute walk test , significant cognitive impairment , pregnancy . Individuals participate others intervention trial also exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>